Skip to content

Egg-Banking and Ovo-donation

Impact of Egg-Banking in an Ovum-donation Program

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00785993
Enrollment
320
Registered
2008-11-05
Start date
2008-11-30
Completion date
2009-10-31
Last updated
2009-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Egg Banking

Keywords

Egg banking, clinical outcome

Brief summary

Egg-banking would considerably simplify the logistics and means by which oocytes could be donated. These banks would make it easier to immediately provide oocytes that would be compatible to the recipient, shortening or even eliminating the problem of long waiting lists. Egg-banking would also allow the oocytes to be effectively quarantined, drastically diminishing the risk of transmission of infectious diseases in a fashion analogous to semen banks. The most essential prerequisite for a successful egg cryo-banking program is to have an efficient oocyte cryopreservation technology. Recent studies, including our own experience, have indicated that vitrified oocytes preserve intact their potential to fertilize and further develop into competent embryos, giving high clinical results as well as high survival rates. The aim of this study is to evaluate impact of the establishment of an egg-banking in our ovum donation program. Oocyte cryopreservation is carried out by Cryotop method. The study includes oocyte donation cycles conducted with fresh and vitrified oocytes. Recipients are allocated randomly into each group (fresh vs. vitrified cycles). Main outcome measures include survival, fertilization, embryo development and clinical outcome.

Interventions

OTHERVitrification of oocytes for IVF treatment
OTHERProtocolary IVF treatment with fresh donor oocytes

Sponsors

Instituto Valenciano de Infertilidad, IVI VALENCIA
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Receptors * Women receiving donor oocytes and whose partners without seere pathology of semen. * BMI \< 25 Donors: Inclusion Criteria: 18 - 35 years oldaños. * Normal Response (8-15 follicles)to long protocol of ovarian stimulation with hCG * Donors with normal menstrual cycles ( 21-35 day duration). * Donors with Body Mass Index (BMI) between 18-25 Kg/m2

Exclusion criteria

* Donors with +/= two previous miscarriages' * Polycystic Ovary Syndrome * Donors with antecedents of poor embrionary quality not attributed to masculine factor. * Donors with decline of Estradiol Hormone of more than 10% or Estradiol Hormone plateau. * Donors with a high response \>20 ovocitos and/or levels above 3000pg/mL of Estradiol the day of the administration of Chorionic gonadotropin (hCG.

Design outcomes

Primary

MeasureTime frame
To evaluate the clinical outcome in an ovum donation program conducted with egg-banking.14 days

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026